Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Elevated plasma level of differentiation inhibitory factor nm23-H1 protein correlates with risk factors for myelodysplastic syndrome

Leukemia volume 16, pages 165–169 (2002)Cite this article

Abstract

We measured plasma nm23-H1 level (nm23-H1), a differentiation inhibitory factor, by an enzyme-linked immunosorbent assay (ELISA) in patients with aplastic anemia (AA) and myelodysplastic syndrome (MDS). The nm23-H1 in AA was not significantly elevated when compared to normal subjects (6.66 ± 1.20 ng/ml vs 5.13 ± 0.81 ng/ml; P = 0.274). In contrast, MDS patients had significantly high levels of nm23-H1 compared not only to normal subjects (11.16 ± 1.42 vs 5.13 ± 0.81 ng/ml; P = 0.0004) but also to those of the AA group (11.16 ± 1.42 ng/ml vs 6.66 ± 1.20 ng/ml; P = 0.018). In the MDS group of patients, no significant difference was observed in the nm23-H1 levels between patients with refractory anemia (RA) and RA with excess blasts (RAEB)/RAEB in transformation (10.71 ± 1.61 ng/ml vs 9.24 ± 2.66 ng/ml; P = 0.672). Of the patients with RA, patients with low risk according to the International Prognostic Scoring System (IPSS) had significantly low levels of nm23-H1 compared to those of IPSS INT-1 level cases (6.40 ± 1.36 ng/ml vs 13.05 ± 2.50 ng/ml; P = 0.0028), suggesting that nm23-H1 may be useful as a prognostic marker for MDS, especially in low risk patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Lowenthal RM, Marsden KA . Myelodysplastic syndrome Int J Hematol 1997 65: 319–338

    Article  CAS  Google Scholar 

  2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C . Proposals for the classification of the myelodysplastic syndromes Br J Haematol 1982 51: 189–199

    Article  CAS  Google Scholar 

  3. Ito Y, Kawanishi Y, Shoji N, Ohyashiki K . Decline in antibiotic enzyme activity in neutrophils is a prognostic factor for infections in patients with myelodysplastic syndrome Clin Infect Dis 2000 31: 1292–1295

    Article  CAS  Google Scholar 

  4. Itoh Y, Kuratsuji K, Aizawa S, Sai M, Ohyashiki K, Toyama K . Superoxide anion production and expression of cytochrome b558 by neutrophils are impaired in some patients with myelodysplastic syndrome Ann Hematol 1991 63: 270–275

    Article  CAS  Google Scholar 

  5. Barrett J, Saunthararajah Y, Molldrem J . Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin Hematol 2000 37: 15–29

    Article  CAS  Google Scholar 

  6. Narayanan MN, Gary CG, Freemont AJ, Kedra JR . Long-term follow-up of aplastic anemia Br J Haematol 1994 86: 837–843

    Article  CAS  Google Scholar 

  7. Bessho F, Ohnishi H, Tabuchi K, Kobayashi M, Hayashi Y . Significance of electron-dense deposits in the mitochondrial matrix of erythroid precursors in aplastic anaemia and myelodysplastic syndrome Br J Haematol 1999 105: 149–154

    Article  CAS  Google Scholar 

  8. Orazi A, Albitar M, Heerema NA, Haskins S, Neiman RS . Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anemia by CD34 and PCNA immunostaining of bone marrow biopsy specimens Am J Clin Pathol 1997 107: 268–274

    Article  CAS  Google Scholar 

  9. Otawa M, Kawanishi K, Iwase O, Shoji N, Miyazawa K, Ohyashiki K . Comparative multi-color flow cytometric analysis of cell surface antigens in bone marrow hematopoietic progenitors between refractory anemia and aplastic anemia Leukemia Res 2000 24: 359–366

    Article  CAS  Google Scholar 

  10. Okabe-Kado J, Kasukabe T, Honma Y, Hayashi M, Henzel WJ, Hozumi M . Identity of a differentiation inhibiting factor for mouse myeloid leukemia cells with NM23/nucleoside diphosphate kinase Biochem Biophys Res Commun 1992 182: 987–994

    Article  CAS  Google Scholar 

  11. Okabe-Kado J, Kasukabe T, Baba H, Urano T, Shiku H, Honma Y . Inhibitory action of nm23 proteins on induction of erythroid differentiation of human leukemia cells Biochim Biophys Acta 1995 1267: 101–106

    Article  Google Scholar 

  12. Yokoyama A, Okabe-Kado J, Sakashita A, Maseki N, Kaneko Y, Hino K, Tomoyasu S, Tsuruoka N, Kasukabe T, Honma Y . Differentiation inhibitory factor nm23 as a new prognostic factor in acute monocytic leukemia Blood 1996 88: 3555–3561

    CAS  PubMed  Google Scholar 

  13. Wakimoto N, Yokoyama A, Okabe-Kado J, Nagata N, Motoyoshi K, Honma Y . Combined analysis of differentiation inhibitory factor nm23-H1 and nm23-H2 as prognostic factors in acute myeloid leukaemia Br J Cancer 1998 77: 2298–2303

    Article  CAS  Google Scholar 

  14. Okabe-Kado J, Kasukabe T, Honma Y . Differentiation inhibitory factor nm23 as a prognostic factor for acute myeloid leukemia Leuk Lymphoma 1998 32: 19–28

    Article  CAS  Google Scholar 

  15. Yokoyama A, Okabe-Kado J, Wakimoto N, Kobayashi H, Sakashita A, Maseki N, Nakamaki T, Hino K, Tomoyasu S, Tsuruoka N, Motoyoshi K, Nagata N, Honma Y . Evaluation by multivariate analysis of the differentiation inhibitory factor nm23 as a prognostic factor in acute myelogeneous leukemia and application to other hematologic malignancies Blood 1998 91: 1845–1851

    CAS  PubMed  Google Scholar 

  16. Okabe-Kado J . Factors inhibiting differentiation of myeloid leukemia cells Crit Rev Oncog 1992 3: 293–319

    CAS  PubMed  Google Scholar 

  17. Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA, Sobel ME . Evidence for a novel gene associated with low tumor metastatic potential J Natl Cancer Inst 1988 80: 200–204

    Article  CAS  Google Scholar 

  18. De la Rosa A, Williams RL, Steeg PS . Nm23/nucleoside diphosphate kinase: toward a structural and biochemical understanding of its biological functions Bioessays 1995 17: 53–62

    Article  CAS  Google Scholar 

  19. Stahl JA, Leone A, Rosengard AM, Porter L, King CR, Steeg PS . Identification of a second human nm23 gene, nm23-H2 Cancer Res 1991 51: 445–449

    CAS  PubMed  Google Scholar 

  20. Venturelli D, Martinez R, Melotti P, Casella I, Peschle C, Cucco C, Spampinato G, Darzynkiewicz Z, Calabretta B . Overexpression of DR-nm23, a protein encoded by a member of the nm23 gene family, inhibits granulocyte differentiation and induces apoptosis in 32Dc13 myeloid cells Proc Natl Acad Sci USA 1995 92: 7435–7439

    Article  CAS  Google Scholar 

  21. Milon L, Rousseau-Merck MF, Munier A, Erent M, Lascu I, Capeau J, Lacombe ML . nm23-H4, a new member of the family of human nm23/nucleoside diphosphate kinase genes localised on chromosome 16p13 Hum Genet 1997 99: 550–557

    Article  CAS  Google Scholar 

  22. Munier A, Feral C, Milon L, Pinon VP, Gyapay G, Capeau J, Guellaen G, Lacombe ML . A new human nm23 homologue (nm23-H5) specifically expressed in testis germinal cells FEBS Lett 1998 434: 289–294

    Article  CAS  Google Scholar 

  23. Gilles AM, Presecan E, Vonica A, Lascu I . Nucleoside diphosphate kinase from human erythrocytes. Structural characterization of the two polypeptide chains responsible for heterogeneity of the hexameric enzyme J Biol Chem 1991 266: 8784–8789

    CAS  PubMed  Google Scholar 

  24. Okada K, Urano T, Goi T, Baba H, Yamaguchi A, Furukawa K, Shiku H . Isolation of human nm23 genomes and analysis of loss of heterozygosity in primary colorectal carcinomas using a specific genomic probe Cancer Res 1994 54: 3979–3982

    CAS  PubMed  Google Scholar 

  25. Willems R, Van Bockstaele DR, Lardon F, Lenjou M, Nijs G, Snoeck HW, Berneman ZN, Slegers H . Decrease in nucleoside diphosphate kinase (NDPK/nm23) expression during hematopoietic maturation J Biol Chem 1998 273: 13663–13668

    Article  CAS  Google Scholar 

  26. Niitsu N, Okabe-Kado J, Kasukabe T, Yamamoto-Yamaguchi Y, Umeda M, Honma Y . Prognostic implications of differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma Blood 1999 94: 3541–3550

    CAS  PubMed  Google Scholar 

  27. Niitsu N, Okabe-Kado J, Nakayama M, Wakimoto N, Sakashita A, Maseki N, Motoyoshi K, Umeda M, Honma Y . Plasma levels of the differentiation inhibitory factor nm23-H1 protein and their clinical implications in acute myelogenous leukemia Blood 2000 96: 1080–1086

    CAS  PubMed  Google Scholar 

  28. Ohara A, Kojima S, Hamajima N, Tsuchida M, Imashuku S, Ohta S, Sasa Okamura J, Sugita K, Kigasawa H, Kiriyama Y, Akatsuka J, Tsukimoto I . Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia Blood 1997 90: 1009–1013

    CAS  PubMed  Google Scholar 

  29. Kaito K, Kobayashi M, Katayama T, Masuoka H, Shimada T, Nishiwai K, Sekita T, Otsubo H, Ogasawara Y, Hosoya T . Long-term administration of G-CSF for aplastic anaemia is closely related to the early evolution of monosomy 7 MDS in adults Br J Haematol 1998 103: 297–303

    Article  CAS  Google Scholar 

  30. Urano T, Fushida S, Fukukawa K, Shiku H . Human nm23-H1 and H2 proteins have similar nucleoside diphosphate kinase activities Int J Oncol 1992 1: 425–430

    CAS  PubMed  Google Scholar 

  31. Testa U, Thomopoulos P, Vinci G, Titeux M, Bettaieb A, Vainchenker W, Rochant H . Transferrin binding to K562 cell line Exp Cell Res 1982 140: 251–260

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We are grateful to Miss Ayako Hirota for her technical assistance. The authors are indebted to Prof J Patrick Barron of the International Medical Communications Center of Tokyo Medical University for his review of this manuscript. This work was supported in part by a Grant-in-Aid of Intractable Hematopoietic Diseases from the Ministry of Health and Welfare, Japan.

Author information

Authors and Affiliations

  1. First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan

    Y Ito, O Iwase, T Shimamoto, JH Ohyashiki & K Ohyashiki

  2. Saitama Cancer Center Research Institute, Saitama, Japan

    J Okabe-Kado & Y Honma

Authors
  1. Y Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Okabe-Kado
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y Honma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. O Iwase
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Shimamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. JH Ohyashiki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K Ohyashiki
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ito, Y., Okabe-Kado, J., Honma, Y. et al. Elevated plasma level of differentiation inhibitory factor nm23-H1 protein correlates with risk factors for myelodysplastic syndrome. Leukemia 16, 165–169 (2002). https://doi.org/10.1038/sj.leu.2402370

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402370

Keywords

Search

Advanced search

Quick links